Key Takeaway
The 2025 VA/DoD lipid guideline formally abandons its longstanding opposition to routine cholesterol monitoring. The updated framework also adopts the PREVENT risk calculator, integrating one-time lipoprotein(a) testing and selective coronary artery calcium scoring into clinical pathways. While moderate-intensity statins maintain their central role in primary prevention, very-high-risk patients with established atherosclerotic cardiovascular disease are now directed toward upfront combination therapy.
The Cholesterol Panel No One Was Supposed to Repeat
Consider a 62-year-old veteran six months out from receiving a stent in the left anterior descending artery. He takes his statin without fail, walks most mornings, and asks his physician a deceptively simple question at follow-up: Is my cholesterol where it needs to be? For years, a clinician adhering strictly to VA/DoD guidelines faced a fraught answer. By asserting that clinical benefit derived entirely from the statin dose rather than the achieved laboratory value, the previous guideline stood virtually alone in actively discouraging routine lipid monitoring. Yet circulating lipid levels reveal critical clinical intelligence: they reflect medication adherence, individual hepatic clearance, and whether an escalating secondary agent is warranted. The 2025 revision finally concedes this clinical reality, fundamentally recalibrating its institutional philosophy.
The Guideline Framework
This publication is not an empirical clinical trial; it is a synopsis of the clinical practice guideline released jointly by the U.S. Department of Veterans Affairs and the U.S. Department of Defense in December 2025. To update the 2020 recommendations, the guideline workgroup collaborated with clinical stakeholders to formulate 12 primary clinical questions and systematically screened English-language literature published between May 16, 2019, and January 15, 2025. Synthesizing this evidence base, the panel formulated 24 recommendations, each graded using the GRADE methodology[1]. The GRADE framework balances the certainty of evidence against the risk-benefit profile, patient values, and implementation feasibility. Consequently, this synopsis does not provide an exhaustive review of lipidology; rather, it serves as an operational roadmap outlining the recalibrated clinical direction adopted by the nation’s largest integrated healthcare system.
Serving as the methodological backbone of the guideline, the GRADE approach weighs the strength of recommendations not merely on empirical certainty, but across the interplay of risk-benefit trade-offs, patient priorities, and resource stewardship. Through this rigorous filter, the panel drew deliberate distinctions between “recommend” (strong recommendation) and “suggest” (weak or conditional recommendation). For instance, while the 2026 ACC/AHA guidelines assign Class 1 (Strong) endorsements to the PREVENT risk tool and coronary artery calcium scoring, the VA/DoD panel positioned both interventions as “weak for” recommendations, citing a paucity of direct prospective trial data proving that these screening modalities independently reduce mortality or hard cardiovascular events. Rather than bureaucratic hesitation, this conservative posture embodies the guideline’s core philosophy of balancing population epidemiology with bedside pragmatism.
Key Findings
The most consequential paradigm shift in the updated guideline is the formal rescission of the previous stance against routine lipid monitoring, alongside the adoption of the PREVENT risk equations for primary prevention risk stratification[1]. To refine clinical decision-making, two diagnostic tools have entered the armamentarium: coronary artery calcium scoring (CAC) is now suggested for patients at intermediate-to-high calculated risk when clinical ambiguity persists, and a one-time measurement of lipoprotein(a) is recommended to identify heightened cardiovascular risk[1].
The guideline also…
